Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.39 |
| ▸ | FLT3 | P36888 | 4/20 | 0.38 |
| ▸ | NRAS | P01111 | 1/20 | 0.38 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 6/20 | 0.36 |
| ▸ | JAK3 | P52333 | 6/20 | 0.36 |
| ▸ | JAK1 | P23458 | 5/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3310129 | 0.89 | FLT3 (0.43) | IGF1RADORA2AFLT3NRASPRMT5 | |
| SCHEMBL3314099 | 0.86 | FLT3 (0.42) | IGF1RADORA2AFLT3NRASJAK2 | |
| SCHEMBL22228874 | 0.83 | MAP3K14 (0.49) | IGF1RFLT3NRASMAP3K14PIK3CA | |
| SCHEMBL22228873 | 0.82 | EIF2AK4 (0.43) | ADORA2A | |
| SCHEMBL22228789 | 0.81 | CLK1 (0.47) | IGF1RFLT3NRAS | |
| SCHEMBL3313303 | 0.80 | IGF1R (0.46) | IGF1RADORA2AFLT3MAP3K14PRMT5 | |
| SCHEMBL28417731 | 0.78 | FLT3 (0.49) | ADORA2AFLT3PRMT5WDR77JAK2 | |
| SCHEMBL1996420 | 0.77 | JAK2 (0.47) | IGF1RADORA2AFLT3PRMT5WDR77 | |
| SCHEMBL3314551 | 0.77 | FLT3 (0.48) | IGF1RFLT3 | |
| SCHEMBL3311479 | 0.76 | IGF1R (0.44) | IGF1RPRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010049731-A1 | PYRAZOLO- AND IMIDAZOPYRIDINYLPYRIMIDINEAMINES AS IGF-1R TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | WO | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | TYMS, ABCG2, UMPS | IGF1R 4384/4885ADORA2A 184/4885FLT3 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.